Content
All Posts > Content under Healthcare
Sector Showcase: "Tale Of Two Halves" Of The Trump Presidency So Far For US Stock Markets
Article By:
Matt Weller
Read
Tuesday, February 21, 2017 2:29 PM EDT
Yesterday's close officially marked 70 trading days since the US election, and while plenty has changed, both for the country and the markets, it's really been a "Tale of Two Halves."
Medtronic Leaves Guidance Unchanged As Q3 Earnings Beat Expectations
Article By:
Lorimer Wilson
Read
Tuesday, February 21, 2017 11:00 AM EDT
Medtronic noted that U.S. revenue gained 4% from last year to $4.106 billion, and represented 56% of its total sales. Non-U.S. developed market revenue gained 6% to $2.193 billion, representing 30% of its total.
In this article: MDT
Healthcare Stock Q4 Earnings Due On Feb 21: HLS, SCAI
Article By:
Zacks Investment Research
Read
Tuesday, February 21, 2017 6:11 AM EDT
Surgical Care Affiliates, Inc. operates surgical facilities, including surgery centers, surgical hospitals, and hospital surgery departments. It serves customers throughout the United States. Surgical Care Affiliates Inc. is based in United States.
Drug Stocks Q4 Earnings Lineup For Feb 21: IRWD, MNTA, EXAS
Article By:
Zacks Investment Research
Read
Tuesday, February 21, 2017 4:30 AM EDT
Momenta’s bottom-line performance has been decent so far, with its earnings surpassing expectations in three of the last four quarters. However, over the trailing four quarters, the company has recorded an average negative surprise of 75.74%.
Rayno Biopharma Portfolio Update
Article By:
Rod Raynovich
Read
Monday, February 20, 2017 11:00 PM EDT
We have updated our biopharmaceuticals portfolio for the period ending February 17 2017. Large caps biopharma stocks have only begun to recover in 2017 after the 2016 earnings release.
Gilead Sciences Receives Canadian Approval For HIV Drug
Article By:
KKD Healthcare Analytics
Read
Monday, February 20, 2017 3:03 PM EDT
Gilead Sciences Inc. announced that it has received approval in Canada for its Odefsey for treating HIV-1 infection.
OncoSec Medical: Promising Cancer Treatment Overlooked By Market
Article By:
Stone Fox Capital
Read
Monday, February 20, 2017 3:43 AM EDT
OncoSec Medical offers an overlooked biotech with a promising proprietary immunotherapy platform with initial clinical trials showing a combination with anti-PD-1 therapies provides a treatment for melanoma cancer and other devastating cancers.
In this article: ONCS
Biotechnology: Poised To Head Higher
Article By:
Tarun Chandra, CFA
Read
Sunday, February 19, 2017 3:23 AM EDT
Biotechnology sector has struggled to overcome regulatory uncertainty. We believe now there is sufficient momentum for Biotechs to breakout and record new 52-week highs compared to a -21% decline in 2016.